retatrutide news today recency 3 Today, we shared new data from two Phase trials of retatrutide, our investigational triple agonist. Learn more: https://go.lilly.com/msrz1v This New Retatrutide Update Can

Based on the current stage of clinical development and estimated trial completion dates registered on ClinicalTrials.gov, a realistic earliest possible timeline might be considered as follows: 20252026: Completion of key phase 3 TRIUMPH trial data 20262027: Potential regulatory submission to the MHRA (and FDA/EMA in parallel) 20272028: Possible MHRA marketing authorisation, subject to satisfactory review 2028 onwards: NICE technology appraisal and potential NHS commissioning decision These timelines are speculative and depend on multiple variables, including trial outcomes, the completeness of the regulatory submission, MHRA review timelines, and NICE deliberations

For some patients: For others: The future role of Retatrutide will become clearer as longer-term data continues to emerge

1mg 2x/week (flat) 2 injections/week P/T Ratio: ~2.1 Use Case: Post-goal maintenance Create Your Custom Microdosing Protocol These pre-built schedules represent common approaches, but optimal dosing varies by individual

Efficacy of once-weekly semaglutide vs empagliflozin added to metformin in type 2 diabetes: Patient-level meta-analysis

Manufacturer patient assistance programs exist but have eligibility requirements and coverage limits

Martn G